NVP-BHG712 alleviates ovariectomy-induced osteoporosis by modulating osteoclastogenesis

Area of Science:

• Biochemistry
• Pharmacology
• Orthopedics

Background:

• Postmenopausal osteoporosis (PMOP) is linked to osteoclast dysfunction.
• Cathepsin K (CTSK) is a critical protein in osteoclast pathogenesis.
• Targeting CTSK offers a potential therapeutic strategy for PMOP.

Purpose of the Study:

• To screen small molecule compounds targeting CTSK for PMOP treatment.
• To evaluate the efficacy of identified compounds in preclinical models.
• To investigate the mechanism of action of promising drug candidates.

Main Methods:

• Molecular docking was used to identify potential CTSK inhibitors.
• In vitro assays assessed compound effects on osteoclast differentiation and CTSK activity.
• In vivo studies utilized an ovariectomy-induced osteoporosis mouse model.
• Analysis included inflammatory factor expression and macrophage polarization.

Main Results:

• NVP-BHG712 was identified as a potent inhibitor of osteoclast differentiation and bone resorption.
• NVP-BHG712 demonstrated strong binding affinity and suppressed CTSK activity.
• The compound modulated inflammatory factors and M1/M2 macrophage balance.
• In vivo, NVP-BHG712 treatment rescued bone loss in an osteoporosis mouse model.

Conclusions:

• NVP-BHG712 shows significant potential as a therapeutic agent for postmenopausal osteoporosis.
• The drug alleviates bone loss by inhibiting excessive osteoclast activation and CTSK function.
• Further research into NVP-BHG712 is warranted for osteoporosis treatment.